1.
Blauvelt A, Conrad C, Costanzo A, van de Kerkhof P, Han G, Langley RG, Davis L, Hoepken B, Wiegratz S, Puig L. Bimekizumab Continuous Maintenance of Eesponse at Every Visit Through Two Years in Patients with Moderate to Severe Plaque Psoriasis: Post-hoc Results from Five Phase 3/3b Trials. J of Skin [Internet]. 2024 Jan. 16 [cited 2024 Jul. 3];8(1):s303. Available from: https://jofskin.org/33014/index.php/skin/article/view/2436